USO 23095

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)

Disease Types: Lung Cancer Research

Eligibility Requirements:

- Age > 18 years old at the time of enrollmen

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Expected life expectancy > 3 months

- Metastatic (Stage IV) NSCLC

- Histologically or cytologically confirmed squamous NSCLC

- Tumor Proportion Score (TPS) with PD-L1 expression percent

- At least one measurable noncerebral lesion according to RECIST 1.1

- No prior systemic treatment for metastatic NSCLC

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Williamsburg
• Virginia Beach (Princess Anne)